This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Vitamin A and pregnancy

Authoring team

There is concern that excessive quantities of vitamin A may have a teratogenic effect. Two metabolites (trans-retinoic acid - RA, tretinoin, and 13-cis retinoic acid - CRA, isotretinoin) are believed to be responsible for this.

  • there are no convincing cases of a foetus being deformed as a result of excessive vitamin A intake from food

  • nevertheless, pregnant women in the UK have been warned against eating liver

  • "women can be assured that eating a balanced diet which does not include liver will provide an adequate vitamin A intake"

  • "there is no reason to change the normal provision of vitamin A supplementation during pregnancy, under the supervision of the general practitioner, midwife or antenatal clinic, provided women are advised of the importance of keeping to the recommended dose"

There have been reports of undesirable side-effects following massive doses of vitamin A supplements in infancy.

NICE state that (2):

  • pregnant women should be informed that vitamin A supplementation (intake greater than 700 micrograms) might be teratogenic and therefore it should be avoided
  • pregnant women should be informed that as liver and liver products may also contain high levels of vitamin A, consumption of these products should also be avoided

Reference:

  1. Bates CJ. Vitamin A. Lancet 1995;345:31-35.
  2. NICE (2008). Antenatal care.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.